We only work on targets and in indications where we believe that Secarna`s LNAplus™ based antisense therapies have the potential to demonstrate superior safety and efficacy benefits over other modalities in development and on the market.

Secarna`s uniquely efficient LNAplus™ discovery process is fueled by our

  • proprietary and streamlined Oligofyer™ bioinformatics systems
  • large in-house cell library and
  • own in vitro screening assays

For subsequent pre-clinical development, Secarna`s molecule design and selection work is complemented by partnerships with internationally renowned centers of excellence across academia and industry.